Clinical trials: Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues
Hepatitis B Virus
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.
- Trial name
- ALTHBV (NCT04231565)
- Testing
- Tenofovir alafenamide Fumarate
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
New Strategy Study of Functional Cure of Chronic Hepatitis B
As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated…
- Trial name
- NCT02605252
- Testing
- Peginterferon alfa-2b
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
This observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis B who have failed antiviral treatment with nucleoside (nucleotide) analogues.
- Trial name
- NCT01794234
- Where
- 9 sites in Poland
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues
Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs
Define the patients who lost HBsAg, studying the loss predictive factors and if there was suspension of treatment, study the evolution after that
- Trial name
- NCT02005146
- Where
- 22 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Hepatitis B, Acute-On-Chronic Liver Failure
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
- Trial name
- HBV (NCT03920618)
- Testing
- Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis B
A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml
A Randomized, open-label, multicenter study. The patients after 1-3 years NAs treatment and having achieved HBeAg loss and HBV DNA <200IU/ml will be switched to Pegasys for 48 or 96 weeks (with a 12 weeks period of overlap with…
- Trial name
- New Switch (NCT01464281)
- Testing
- Peginterferon alfa 2a
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Chronic Hepatitis B
Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues
Antiviral therapy is the most important method to slow and stop the progress of the disease in patients with chronic hepatitis B (CHB).
- Trial name
- NCT02362490
- Testing
- peginterferon alpha 2a
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Ditan Hospital